Patients have follow-up visits at two weeks, six weeks, four months, 10 months and then annually to ensure they stay on track
The most common cause for injection site redness is the skin or the immune system's response to the needle or the medicine
You've probably read all about injection schedules, dosing protocols, and lab values
Not because it finishes the job, but because it makes the job look finished enough that Lilly can pivot resources to what comes next
The modelling framework aimed to translate the primary clinical benefits demonstrated in the STEP 1, ESSENCE, and SELECT trials, namely, weight reduction, improvement in liver fibrosis status and cardiovascular risk reduction, into health-economic outcomes, by linking these effects to reductions in comorbidities and improvements in quality of life among obese patients with MASH
The LEADER trial (cardiovascular outcomes study in type 2 diabetes) showed that liraglutide, a similar GLP-1 agonist, reduced major adverse cardiac events by 13%